4D Molecular Therapeutics (FDMT) EPS (Basic) Growth (1y) (2021 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 87.85% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 143.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 322.67% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -16.29% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.41% |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | -6.20% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6.20% |
| Mar 31, 2026 | -17.39% |
| Dec 31, 2025 | 136.36% |
| Sep 30, 2025 | -28.40% |
| Jun 30, 2025 | -54.57% |
| Mar 31, 2025 | -30.87% |
| Dec 31, 2024 | -11.61% |
| Sep 30, 2024 | -225.16% |
| Jun 30, 2024 | 18.16% |
| Mar 31, 2024 | 24.97% |
| Dec 31, 2023 | 2.52% |
| Sep 30, 2023 | 69.40% |
| Jun 30, 2023 | 11.09% |
| Mar 31, 2023 | -7.27% |
| Dec 31, 2022 | 6.44% |
| Sep 30, 2022 | 3.61% |
| Jun 30, 2022 | -206.14% |
| Mar 31, 2022 | -32.93% |
| Dec 31, 2021 | 71.69% |
| Sep 30, 2021 | 45.39% |